Pohl R B, Wolkow R M, Clary C M
Department of Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, USA.
Am J Psychiatry. 1998 Sep;155(9):1189-95. doi: 10.1176/ajp.155.9.1189.
This study determined the efficacy and safety of sertraline in the treatment of patients with panic disorder.
The study was a randomized, double-blind, parallel-group, flexible-dose comparison of sertraline and placebo in outpatients with a DSM-III-R diagnosis of panic disorder with or without agoraphobia. After a 2-week single-blind placebo lead-in, 168 patients entered a 10-week double-blind phase in which they were randomly assigned to treatment with either sertraline or placebo.
Sertraline was significantly more effective than placebo in decreasing the number of full and limited-symptom panic attacks. Among patients who completed the study, the mean number of panic attacks per week dropped by 88% in the sertraline-treated patients and 53% in the placebo-treated patients. Sertraline-treated patients also had significantly more improvement than placebo-treated patients in scores on the Quality of Life Enjoyment and Satisfaction Questionnaire, patient global evaluation, and Clinical Global Impression severity of illness and global improvement scales. Overall, patients tolerated sertraline well, and only 9% terminated treatment because of side effects.
Sertraline is an effective and well-tolerated treatment for patients with panic disorder.
本研究确定了舍曲林治疗惊恐障碍患者的疗效和安全性。
该研究是一项随机、双盲、平行组、灵活剂量的舍曲林与安慰剂对比试验，受试对象为符合《精神疾病诊断与统计手册》第三版修订版（DSM-III-R）诊断标准的伴或不伴有广场恐惧症的惊恐障碍门诊患者。在为期2周的单盲安慰剂导入期后，168名患者进入为期10周的双盲阶段，在此期间他们被随机分配接受舍曲林或安慰剂治疗。
在减少完全症状性和有限症状性惊恐发作次数方面，舍曲林显著优于安慰剂。在完成研究的患者中，接受舍曲林治疗的患者每周惊恐发作的平均次数下降了88%，而接受安慰剂治疗的患者下降了53%。在生活享受与满意度问卷得分、患者整体评估以及临床总体印象疾病严重程度和总体改善量表方面，接受舍曲林治疗的患者也比接受安慰剂治疗的患者有更显著的改善。总体而言，患者对舍曲林耐受性良好，只有9%的患者因副作用而终止治疗。
舍曲林是治疗惊恐障碍患者的一种有效且耐受性良好的药物。
